Back to results

RecruitingPhase 3

Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia

NCT06597006

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

UC San Francisco Medical Center

San Francisco, California, United States

+17 additional locations

Contact

Novartis Pharmaceuticals

1-888-669-6682 novartis.email@novartis.com

View on ClinicalTrials.gov

Save this trial

Quick facts

Start date: 2025-02-28
Enrollment: 9 participants
Sponsor: Novartis Pharmaceuticals
Purpose: treatment

Locations (18)

UC San Francisco Medical CenterSan Francisco, California, United States
UC San Francisco Medical CenterSan Francisco, California, United States
Childrens National HospitalWashington D.C., District of Columbia, United States
Washington Univ School Of MedicineSt Louis, Missouri, United States
Novartis Investigative SiteVienna, Austria
Novartis Investigative SiteBeijing, Beijing Municipality, China
Novartis Investigative SiteFrankfurt am Main, Hesse, Germany
Novartis Investigative SiteIoannina, Greece
Novartis Investigative SiteThessaloniki, Greece
Novartis Investigative SiteKota Bharu, Kelantan, Malaysia
Novartis Investigative SiteAmsterdam, North Holland, Netherlands
Novartis Investigative SiteBloemfontein, Free State, South Africa
Novartis Investigative SiteTaichung, Taiwan
Novartis Investigative SiteTaipei, Taiwan
Novartis Investigative SiteAdana, Saricam, Turkey (Türkiye)
Novartis Investigative SiteAnkara, Yenimahalle, Turkey (Türkiye)
Novartis Investigative SiteIzmir, Turkey (Türkiye)
Novartis Investigative SiteSouthampton, United Kingdom

Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia — TrialFind